Amgen said that the approval for Repatha (evolocumab) in Japan filed by Amgen Astellas Biopharma K.K., a joint venture with Tokyo-based Astellas Pharma, could be launched within months pending reimbursement details.
Astellas Pharma has signed its second tech-enabled drug repurposing deal in as many months. The latest deal connects Astellas to NuMedii, a digital drug discovery shop cofounded by Atul Butte that lists Allergan among its clients.
The National Institutes of Health (NIH) has said that it would take "extraordinary" circumstances for the agency to address rising drug prices, even as skyrocketing costs draw criticism from patients, payers and the public. But two organizations think that it's about time for the NIH to act. And they're not mincing words with their request.
The U.S. arm of Tokyo-based Astellas Pharma and U.S.-listed Medivation said enzalutamide met its primary endpoint in a Phase II study to treat metastatic castration-resistant prostate cancer (mCRPC).
In 2015, the FDA by its own account approved 45 new drugs, the largest one-year tally since 1996, which wrapped up with a record 53 regulatory OKs. Now, here's the full list of new drugs approved by the FDA in 2015, in chronological order.
Astellas has turned to Biovista for help finding new indications for some of its existing compounds. The project is underpinned by Biovista's Clinical Outcome Search Space technology, a tool that combines literature searches and in silico modeling to spot links between drugs and targets.
Japan's Astellas Pharma sold its dermatology business to Danish specialty product firm LEO in a deal that will free up cash from a unit that analysts have long said is non-core and which follows a high profile move this week to splash out $379 million to buy U.S-based regenerative ophthalmology biotech Ocata Therapeutics.
Japan's Astellas Pharma said it is paying $379 million in case to buy Ocata Therapeutics, a biotechnology cmpany that specializes in regenerative drugs to treat macular degeneration, according to a report by the Boston Globe.
Astellas Pharma has stepped up with a $379 million bid for Ocata Therapeutics, a pioneering--and often controversial--stem cell company that has managed to survive a years-long roller coaster ride through the hype, hope and disappointments of the past decade.
Astellas Pharma and Japan university researchers say they have succeeded with preclinical work showing that induced pluripotent stem cells are capable of improving the symptoms of kidney failure.